<SEC-DOCUMENT>0000856982-24-000087.txt : 20240918
<SEC-HEADER>0000856982-24-000087.hdr.sgml : 20240918
<ACCEPTANCE-DATETIME>20240918162537
ACCESSION NUMBER:		0000856982-24-000087
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240916
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240918
DATE AS OF CHANGE:		20240918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERIT MEDICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000856982
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870447695
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-18592
		FILM NUMBER:		241307872

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST MERIT PARK WAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		8012531600

	MAIL ADDRESS:	
		STREET 1:		1600 WEST MERIT PARKWAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mmsi-20240918x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 9/18/2024 7:37:45 PM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: a4ac999a-b275-4629-8fad-b531b845a657 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mmsi="http://www.meritmedical.com/20240918" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityCentralIndexKey" id="Tc_87wxZxlS3k-thngWsKY_jg_2_1">0000856982</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:AmendmentFlag" id="Tc_A3ydQl1A1UCW6xod3abACg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mmsi-20240918.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000856982</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-17</xbrli:startDate><xbrli:endDate>2024-09-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:50.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_e89782ce_c799_4122_88dc_e410decb6ea3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:DocumentType" id="Narr_4Iq6rLd72UKJYJMAOFBDWg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_NmcFN7QL8kGJ8YHc1sV_oA"><span style="font-size:9pt;">September 16, 2024</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mmsi-20240918x8k001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;width:279.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityRegistrantName" id="Narr_cDbhrTtptE-NW38RgEifug"><b style="font-weight:bold;">Merit Medical Systems,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_482e885a_2d52_4623_b7e4_21eef4425b9e"></a><a id="Tc_A2T5boyz-UWXz2twUk3Mqg_2_0"></a><a id="Tc_No6g55YML0WHw0vojW9vaA_2_2"></a><a id="Tc_ckbBty6hhESaSw80JTYeOA_2_4"></a><a id="Tc_A5ho31ACB0mgzdRftLeDIA_3_0"></a><a id="Tc_q-tdfYksBkqjZQ8o3qb5pg_3_2"></a><a id="Tc_wVCUuPOQu0avNm0Ps2mGTw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_zkdtkvHeTEmek2wnEWOAaQ_1_0"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityFileNumber" id="Tc_0HGl6QAlj0uvsfDvDepnnQ_1_2"><b style="font-size:9pt;font-weight:bold;">0-18592</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityTaxIdentificationNumber" id="Tc_YJ-sTADoHkS472B9kDdh6A_1_4"><b style="font-size:9pt;font-weight:bold;">87-0447695</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_7d471683_06d1_45fe_9287_288340eace6c"></a><a id="Tc_aYHlCesR-0Oist_BqOwrgg_2_0"></a><a id="Tc_Ip0P3vGIwEiAdOkeJ_39QA_3_0"></a><a id="Tc_GgtgTSsgYUKpgLAi__eNjg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityAddressAddressLine1" id="Tc_jZ0DgiLzaEiQxHeBliG3cQ_1_0"><b style="font-size:9pt;font-weight:bold;">1600 West Merit Parkway</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityAddressCityOrTown" id="Narr__mXkUExE90ywR761_t2qug"><b style="font-size:9pt;font-weight:bold;">South Jordan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_FGbqA6Mk2Ey641J8piek7A"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:EntityAddressPostalZipCode" id="Tc_NnwW4VXm1ECn1dYH2m8zvA_2_2"><b style="font-size:9pt;font-weight:bold;">84095</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:CityAreaCode" id="Narr_e4PKTj8oWEmz5z0Hb47dMA"><b style="font-size:9pt;font-weight:bold;">801</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:LocalPhoneNumber" id="Narr_QHP38LXNVkC5WZP7CqOMwg"><b style="font-size:9pt;font-weight:bold;">253-1600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant's telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_2P5xcf4T7EqFbzpmZvDnNg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_lqMM1pAYSEiFY3Ok-1zrZQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_7g5WBL9TeUCSw8humoZAIw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_gtKTWWl5TECZ2eN6hEe1qg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_e1adca4e_7a42_4339_9783_775404ac1f0f"></a><a id="Tc_4FbrhQbbvUigMtW_8Yobig_1_0"></a><a id="Tc_JPmUb1AcKkGtVQ3P2ajk2Q_1_2"></a><a id="Tc_tVMsPNSzLEyhucjKdxAPBA_1_4"></a><a id="Tc_Rc6HnlMiOUOpHanprXMeUA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Trading&#160;Symbol(s)</p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</p></td></tr><tr><td style="vertical-align:top;width:31.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:Security12bTitle" id="Tc_ydXO0Gl2AECAO6VJJwUYvg_2_0"><span style="font-size:9pt;">Common Stock, no par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:TradingSymbol" id="Tc_HWh8ooKUAk6MXDUmtlW9Eg_2_2"><span style="font-size:9pt;">MMSI</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" name="dei:SecurityExchangeName" id="Narr_nSyZqrO4FUKGhfslEP8LFw"><span style="font-size:9pt;">NASDAQ</span></ix:nonNumeric><span style="font-size:9pt;"> Global Select Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_80zT4SGSnU-R39Xwgo-FUg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_08824d09_7403_4671_8f63_b65f0d528806"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1.01. &#160;Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2024, Merit Medical Systems, Inc., a Utah corporation (&#8220;Merit&#8221;), entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cook Medical Holdings LLC, an Indiana limited liability company (&#8220;Cook Medical&#8221;), to purchase Cook Medical&#8217;s lead management portfolio of medical devices and certain related assets for total cash consideration of approximately $210 million (collectively, the &#8220;Acquisition&#8221;). Merit expects to fund the Acquisition through a combination of cash on hand and borrowings under its long-term credit facility. The closing of the proposed Acquisition is expected to occur during the fourth quarter of 2024, subject to the receipt or waiver (in accordance with the provisions of the Purchase Agreement) of certain closing conditions, including clearance under the Hart-Scott-Rodino&#160;Antitrust Improvements Act of 1976, and other customary closing conditions. In connection with the projected closing of the Acquisition, Merit proposes to enter into a transition services agreement with Cook Medical, pursuant to which Cook Medical would provide manufacturing and other services to Merit during a two-year transition period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Purchase Agreement contains customary representations and warranties, as well as customary indemnification provisions and post-closing covenants. The representations and warranties are insured pursuant to a buyer-side representation and warranty insurance policy (the &#8220;RWI&#8221;), subject to standard exceptions and limitations, obtained by Merit in connection with the Acquisition. Recovery under the RWI is Merit&#8217;s sole recourse for breaches of representations and warranties, other than with respect to fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The foregoing summary of the principal terms of the Purchase Agreement is not complete and is qualified in its entirety by the actual terms and conditions of the Purchase Agreement, a copy of which Merit intends to file in a future filing with the SEC. The representations, warranties, and other terms contained in the Purchase Agreement were made solely for the purposes of such agreement and as of specified dates, were solely for the benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties. Those representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Purchase Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Merit, Cook Medical, any of their respective subsidiaries or affiliates, or the assets or business that Merit proposes to acquire pursuant to the Acquisition. Accordingly, investors should not rely on the representations and warranties as characterizations of the actual state of facts, since (i) they were made only as of the date of the Purchase Agreement or prior, specified dates, (ii) in some cases they are subject to qualifications with respect to materiality, knowledge and/or other matters, and (iii) they may be modified in important part by the underlying exhibits and schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_497f0c96_8682_4d34_88dc_0b404053c9b3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 2.02.  Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On September 17, 2024, Merit issued a press release announcing the Acquisition (the &#8220;Acquisition Press Release&#8221;) and updating its 2024 fiscal year financial guidance in light of the Acquisition. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this &#8220;Current Report&#8221;) and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_a3489945_b319_4879_af9f_7d035d5a82d6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="color:#212529;font-size:9.5pt;background:#ffffff;">On September 16, 2024, Merit issued a press release announcing the </span><span style="font-size:10pt;">six-month findings of its </span><span style="color:#212529;font-size:10pt;background:#ffffff;">WRAPSODY&#8482; Arteriovenous Access Efficacy (WAVE) pivotal trial.</span><span style="font-size:10pt;"> </span><span style="color:#212529;font-size:9.5pt;background:#ffffff;">A copy of the press release is furnished as Exhibit 99.2 to this Current Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 17, 2024, Merit issued the Acquisition Press Release (Exhibit 99.1) announcing the Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information contained in Item 2.02 above and this Item 7.01 of this Current Report (including Exhibits 99.1 and 99.2 attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Merit is making reference to non-GAAP financial information in the Acquisition Press Release. A quantitative reconciliation of such non-GAAP financial information to comparable GAAP financial information is not available without unreasonable effort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information included in this Current Report contains forward-looking statements about Merit that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and Section 27A of the Securities Act. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;objective&#8221; or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain such identifying words. All statements included in this Current Report, other than statements of historical fact, are forward-looking statements for purposes of the Exchange Act and the Securities Act, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives for future operations, any statements concerning proposed new products or services, any statements regarding the integration, development or commercialization of the business or any assets acquired from other parties, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. Additionally, forward-looking statements include, among other things, the expected timing of the closing of the Acquisition, the ability of Merit and Cook Medical to satisfy the closing conditions under the Purchase Agreement (including the execution of related agreements referenced in the Purchase Agreement), the receipt of required regulatory approvals, and the estimated or anticipated benefits of the Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merit&#8217;s actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by these forward-looking statements, including those risks, uncertainties and other factors described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and Merit&#8217;s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and June 30, 2024, and subsequent filings with the SEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All forward-looking statements included in this Current Report speak only as of the date made, are based on information available to Merit as of such date, and are subject to change. Merit assumes no obligation to update or revise any forward-looking statement. If Merit does update or correct one or more forward-looking statements, readers should not conclude that Merit will make additional updates or corrections. Merit&#8217;s actual results will likely differ, and may differ materially, from anticipated results. Readers should not unduly rely on any such forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4d070440_9921_471a_9fd3_1a1e9c70e24f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01. &#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:34.5pt;"><td style="vertical-align:bottom;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;NUMBER</b></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION</b></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">99.1</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mmsi-20240918xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated September 17, 2024, entitled &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Merit Medical Signs Agreement to Purchase Lead Management Portfolio from Cook Medical</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8221;</span></a></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">99.2</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mmsi-20240918xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated September 16, 2024, entitled &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Merit Medical&#8217;s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients&#8221;</span></a></p></td></tr><tr style="height:15.4pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">104</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_db270cfa_c35d_4d0d_8197_9158b5bf4fb1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.8%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MERIT MEDICAL SYSTEMS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: September 18, 2024</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;">/s/ Brian G. Lloyd</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian G. Lloyd</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mmsi-20240918xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 9/18/2024 07:37:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"><img src="mmsi-20240918xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:75.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:468pt;"></font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><div style="display:inline-block;width:466.5pt;"><div style="left:0pt;padding-bottom:1.05pt;position:relative;top:0pt;width:465.75pt;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:465.75pt;"><div style="left:0pt;position:relative;text-indent:0pt;top:0pt;"><div align="left"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:16pt;height:max-content;line-height:1.28;margin-bottom:0pt;margin-top:0pt;padding-left:0pt;padding-right:0pt;width:311.7pt;"><tr style="height:1pt;"><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contacts:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PR/Media Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sarah Comstock&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit Medical&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investor Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mike Piccinino, CFA, IRC&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Westwicke - ICR&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-801-432-2864&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-443-213-0509&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">sarah.comstock@merit.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">mike.piccinino@westwicke.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;width:100%;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">Merit Medical Signs Agreement to Purchase Lead Management Portfolio from Cook Medical&#174;</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Asset acquisition of Cook Medical&#8217;s end-to-end lead management product portfolio strengthens Merit&#8217;s existing electrophysiology and CRM business </i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Asset acquisition projected to add approximately $40 million of revenue, on an annualized basis beginning in fiscal year 2025, with a solid growth profile serving an underpenetrated global lead management market </i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Merit reaffirms full-year 2024 financial guidance previously issued on August 1, 2024, and updates full-year 2024 financial guidance to include the projected impact from this acquisition post-close</i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">SOUTH JORDAN, Utah, September 17, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced it has signed a definitive asset purchase agreement to purchase Cook Medical&#8217;s lead management portfolio for total cash consideration of approximately $210 million. Merit expects to fund the transaction through a combination of cash on hand and borrowings under its long-term credit facility. The closing of the proposed transaction is expected to occur during the fourth quarter of 2024, subject to the receipt or waiver (in accordance with the provisions of the asset purchase agreement) of certain closing conditions, including clearance under the Hart-Scott-Rodino&#160;Antitrust Improvements Act of 1976, and other customary closing conditions. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cook Medical&#8217;s lead management business has 34 years of operating history and provides a comprehensive end-to-end product portfolio of medical devices and accessories used in lead management procedures for patients who need a pacemaker or an implantable cardioverter-defibrillator (ICD) lead removed or replaced. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;This transaction is consistent with our Continued Growth Initiatives (CGI) and positions Merit to offer clinicians an increasingly comprehensive set of solutions to support cardiac intervention patients, from diagnosis, to therapy and intervention, to post-procedure care,&#8221; said Fred P. Lampropoulos, Merit&#8217;s Chairman and Chief Executive Officer. &#8220;We believe this transaction will strengthen our fast-growing, high-margin electrophysiology and CRM business with the addition of differentiated products and an established commercial infrastructure. We believe the transaction will enhance our position in the cardiac intervention market, which we estimate represents an annual addressable opportunity of more than $900 million in the US, EMEA and APAC regions. Specifically, beginning in fiscal year 2025, the addition of Cook&#8217;s lead management business positions Merit to represent more than $100 million in combined annualized electrophysiology and cardiac rhythm management revenue serving the global cardiac intervention market.&#8221;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mr. Lampropoulos continued: &#8220;We have updated our full-year 2024 financial guidance to include the projected impact of this acquisition from a prospective closing date of October 31, 2024 to December 31, 2024 and, importantly, we have reaffirmed our updated full-year 2024 financial guidance previously issued on August 1, 2024. While we anticipate the transaction will be modestly dilutive to our full-year 2024 non-GAAP profitability given the partial-year contribution, we believe the financial profile of this acquisition is very attractive and is consistent with our goal of delivering sustainable, constant currency growth, improving profitability and strong free cash flow generation. We look forward to discussing this acquisition and our updated outlook for 2024 on our third quarter earnings report on October 30, 2024.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP net income; non-GAAP earnings per share; non-GAAP gross margin; non-GAAP operating margin and constant currency revenue are non-GAAP financial measures. A description of these financial measures is included under the heading &#8220;Non-GAAP Financial Measures&#8221; below. A quantitative reconciliation of such financial measures to comparable GAAP financial measures is not available without unreasonable effort.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Summary</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit believes that the assets it proposes to acquire from Cook Medical generated approximately $37 million of revenue over the twelve-month period ended December 31, 2023, with sales to customers in the US, EMEA, APAC and ROW representing approximately 41%, 42%, 11% and 6%, respectively. If the proposed transaction (including Merit&#8217;s proposed execution of a transition services agreement pursuant to which Cook Medical would provide manufacturing and other services to Merit during a two-year transition period) is consummated, of which there can be no assurance, the assets Merit proposes to acquire from Cook Medical, are projected to contribute revenue, from a projected closing date of October 31, 2024 through December 31, 2024, in the range of $4 to $6 million and are projected, during the same period of time, to dilute Merit&#8217;s previously forecasted non-GAAP operating margin, non-GAAP net income and non-GAAP earnings per share, inclusive of approximately $1.8 million of lower interest income on cash balances used for the total purchase consideration and excluding approximately $1.9 million of non-cash and non-recurring transaction-related expenses, and to be dilutive to Merit&#8217;s full-year 2024 GAAP net income and GAAP earnings per share. The acquisition is projected to be accretive to non-GAAP gross margin, accretive to non-GAAP operating margin in the first full-year post close, and accretive to non-GAAP net income and non-GAAP earnings per share in the second full-year post close. The acquisition, if completed, is projected to be dilutive to Merit&#8217;s GAAP net income and GAAP earnings per share in the first full-year post close, neutral in the second-full year post close and accretive thereafter.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Updated Fiscal Year 2024 Financial Guidance</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s updated full-year 2024 financial guidance now reflects the projected impacts of the acquisition of Cook Medical&#8217;s lead management business from a projected closing date of October 31, 2024 through December 31, 2024. Merit is otherwise reaffirming prior full-year 2024 financial guidance previously announced on August 1, 2024.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Based upon the information currently available to Merit&#8217;s management, for the year ending December 31, 2024, after giving effect to the projected contribution of the assets proposed to be acquired from Cook Medical, assuming the proposed acquisition closes on October 31, 2024 and absent material acquisitions, non-recurring transactions or other factors beyond Merit&#8217;s current expectations, Merit now expects the following financial results:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue and Earnings Guidance* </i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:34.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Updated Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:34.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prior Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year Ending</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">% Change </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year Ending</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">% Change </b></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Financial Measure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Y/Y</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Y/Y</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Sales</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$1.339&#160;- $1.351 billion</b></p></td><td style="vertical-align:bottom;width:12.38%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.5% - 7.5%</b></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$1.335&#160;- $1.345 billion</b></p></td><td style="vertical-align:bottom;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6% - 7%</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Cardiovascular Segment</font></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$1.285&#160;- $1.295 billion</font></p></td><td style="vertical-align:bottom;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.3% - 6.1%</font></p></td><td style="vertical-align:bottom;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$1.281&#160;- $1.289 billion</font></p></td><td style="vertical-align:bottom;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5% - 6%</font></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Endoscopy Segment</font></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$54&#160;- $56 million</font></p></td><td style="vertical-align:bottom;width:12.38%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">45% - 52%</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$54&#160;- $56 million</font></p></td><td style="vertical-align:bottom;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">45% - 52%</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:29.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-GAAP</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.38%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:21.95%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Earnings Per Share</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$3.25 - $3.34</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">14% - 17%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.95%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$3.27 - $3.35</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">15% - 17%</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">*Percentage figures approximated; dollar figures may not foot due to rounding</i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.2%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:22.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:0.75pt;"><td style="vertical-align:bottom;width:25.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:top;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:22.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:19.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:0.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:top;width:18.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation* </i></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Updated Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prior Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2024 Net Sales Guidance - % Change from Prior Year (GAAP) </font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">6.5%</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.5%</font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">6.2%</font></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.0%</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Estimated impact of foreign currency exchange rate fluctuations</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.7%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.7%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.7%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.7%</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) </font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.2%</font></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">8.2%</font></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">6.9%</font></p></td><td style="vertical-align:bottom;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.7%</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">*Percentage figures approximated and may not foot due to rounding</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-bottom:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><i style="color:#293849;font-family:'Times New Roman','Times','serif';font-style:italic;">(1)</i><sup style="color:#293849;font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:italic;vertical-align:top;"> </sup><i style="color:#293849;font-family:'Times New Roman','Times','serif';font-style:italic;">&#8220;Updated Guidance&#8221; reflects Merit&#8217;s full-year 2024 financial guidance, previously introduced on August 1, 2024, plus the projected impacts of the acquisition of assets from Cook Medical from a projected closing date of October 31, 2024 through December 31, 2024.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><i style="color:#293849;font-family:'Times New Roman','Times','serif';font-style:italic;">(2) &#8220;Prior Guidance&#8221; reflects Merit&#8217;s full-year 2024 financial guidance, previously introduced on August 1, 2024, excluding the acquisition of the assets of Cook Medical.</i><font style="color:#293849;font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s financial guidance for the&#160;year ending December&#160;31, 2024 is subject to risks and uncertainties identified in this release and Merit&#8217;s filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advisors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Wells Fargo acted as financial advisor to Merit and Bank of America Securities acted as financial advisor to Cook Medical. Parr Brown Gee &amp; Loveless served as legal advisor to Merit. Ice Miller served as legal advisor to Cook Medical.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-GAAP Financial Measures </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Although Merit&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America, Merit&#8217;s management believes that the non-GAAP financial measures referenced in this release may provide investors with useful information regarding the underlying business trends and performance of Merit&#8217;s ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures referenced in this release include: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></font><font style="font-family:'Times New Roman','Times','serif';">constant currency revenue; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP gross profit and margin; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP operating income and margin; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP net income; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></font><font style="font-family:'Times New Roman','Times','serif';">non-GAAP earnings per share. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s management team uses these non-GAAP financial measures to evaluate Merit&#8217;s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit&#8217;s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Readers should consider non-GAAP measures referenced in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit&#8217;s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP earnings per share, non-GAAP gross profit and margin, non-GAAP operating income and margin, and non-GAAP net income because such amounts in any specific period may not directly correlate to the underlying performance of Merit&#8217;s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information referenced in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures referenced in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures and not to rely on any single financial measure to evaluate Merit&#8217;s business or results of operations. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Constant Currency Revenue </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the US dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the US dollar.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP Gross Profit and Margin </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP Operating Income and Margin </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit&#8217;s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP Net Income </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, changes in tax regulations, and other items.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-GAAP EPS </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ABOUT MERIT MEDICAL</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ABOUT COOK MEDICAL</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we invent, manufacture and deliver a unique portfolio of medical devices to the healthcare systems of the world. Serving patients is a privilege, and we demand the highest standards of quality, ethics and service. We have remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit&#8217;s forecasted plans, revenues, net sales, net income (GAAP and non-GAAP), operating income and margin (GAAP and non-GAAP), gross profit and margin (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), and other financial measures, future growth and profit expectations or forecasted economic conditions, or the implementation of, and results which may be achieved through, Merit&#8217;s Continued Growth Initiatives program or other expense reduction initiatives, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to risks and uncertainties such as those described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#8220;2023 Annual Report&#8221;) and other filings with the SEC. Such risks and uncertainties include inherent risks and uncertainties associated with Merit&#8217;s proposed acquisition of Cook Medical&#8217;s lead management portfolio and integration of the assets and operations proposed to be acquired from Cook Medical and its ability to achieve projected </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">financial results, product development and other anticipated benefits of the proposed acquisition; uncertainties as to whether Merit will be successful in completing the proposed acquisition, including the risk that conditions to closing the proposed acquisition will not be satisfied; uncertainties as to whether, if the acquisition of the Cook Medical lead management portfolio is completed, Merit will achieve sales, gross and operating margin, net income and earnings per share performance consistent with its forecasts projected for the acquisition; disruptions in Merit&#8217;s supply chain, manufacturing or sterilization processes; reduced availability of, and price increases associated with, commodity components and other raw materials; adverse changes in freight, shipping and transportation expenses; negative changes in economic and industry conditions in the United States or other countries, including inflation; risks relating to Merit&#8217;s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; risks associated with Merit&#8217;s ongoing or prospective manufacturing transfers and facility consolidations; fluctuations in interest or foreign currency exchange rates; risks and uncertainties associated with Merit&#8217;s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Office of Inspector General &#8211; Department of Health and Human Services; difficulties, delays and expenditures relating to development, testing and regulatory approval or clearance of Merit&#8217;s products, including the pursuit of approvals under the European Union Medical Device Regulation, and risks that such products may not be developed successfully or approved for commercial use; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit&#8217;s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; restrictions on Merit&#8217;s liquidity or business operations resulting from its debt agreements; infringement of Merit&#8217;s technology or the assertion that Merit&#8217;s technology infringes the rights of other parties; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, including reforms to the procedures for approval or clearance of Merit&#8217;s products by the U.S. Food &amp; Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other jurisdictions; termination of relationships with Merit&#8217;s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit&#8217;s existing or future products obsolete; market acceptance of new products; dependance on distributors to commercialize Merit&#8217;s products in various jurisdictions outside the United States; volatility in the market price of Merit&#8217;s common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; failure to introduce products in a timely fashion; price and product competition; fluctuations in and obsolescence of inventory; and other factors referenced in the 2023 Annual Report and other materials filed with the SEC. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRADEMARKS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors. Cook Medical is a trademark of Cook Medical LLC.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>mmsi-20240918xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 9/18/2024 07:37:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT 99.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"><img src="mmsi-20240918xex99d2001.jpg" alt="Graphic" style="display:inline-block;height:75.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:468pt;"></font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><div style="display:inline-block;width:466.5pt;"><div style="left:0pt;padding-bottom:1.05pt;position:relative;top:0pt;width:465.75pt;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:465.75pt;"><div style="left:0pt;position:relative;text-indent:0pt;top:0pt;"><div align="left"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:16pt;height:max-content;line-height:1.28;margin-bottom:0pt;margin-top:0pt;padding-left:0pt;padding-right:0pt;width:311.7pt;"><tr style="height:1pt;"><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contacts:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PR/Media Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sarah Comstock&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit Medical&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investor Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mike Piccinino, CFA, IRC&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Westwicke - ICR&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-801-432-2864&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-443-213-0509&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.3pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">sarah.comstock@merit.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.35pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">mike.piccinino@westwicke.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;width:100%;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">Merit Medical&#8217;s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">In the US pivotal trial,</i><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">WRAPSODY achieved 89.8% target lesion primary patency at 6 months. </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">SOUTH JORDAN, Utah, September 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive 6-month findings from the randomized arteriovenous (AV) fistula arm of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) during a FIRST@CIRSE presentation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WRAPSODY is a cell-impermeable endoprosthesis which is intended to extend long-term vessel patency in dialysis patients. Many patients undergoing dialysis rely on a vascular access site created in the arm called an AV fistula. The maintenance of adequate blood flow through this site is crucial for patient survival. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The AV fistula arm of the WAVE trial enrolled 245 patients at 43 sites. Patients were randomized 1:1 to WRAPSODY or percutaneous transluminal angioplasty (PTA). Target lesion primary patency in patients treated with WRAPSODY was 27 percentage points higher than patients in the PTA cohort (89.8% vs. 62.8%, p&lt;0.0001).</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#footnote-2">1</a></sup><font style="font-family:'Times New Roman','Times','serif';"> The proportion of patients who experienced an adverse event was similar between cohorts.</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#footnote-3">2</a></sup></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;The superiority of the six-month efficacy data is compelling and provides clinicians the chance to evaluate how WRAPSODY can help us prolong the vascular access of our patients. WRAPSODY should be the new standard of care for these patients,&#8221; said Mahmood K. Razavi, MD, FSIR, FSVM, Interventional Radiologist and Medical Director of Clinical Research at St. Joseph Heart and Vascular Center in Orange, Calif., and Co-Principal Investigator of the WAVE trial. &#8220;Meeting with colleagues at CIRSE to discuss the AV fistula arm of the WAVE study was the first of what we hope to be many productive discussions,&#8221; said Robert G. Jones, FRCR, Consultant Interventional Radiologist at Queen Elizabeth Hospital Birmingham in Birmingham, England, and Co-Principal Investigator of the WAVE study. &#8220;The potential for WRAPSODY to help us safely extend vascular access for our patients is a vital component of care.&#8221; </font></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="footnote-2"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;"><sup style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;">1</sup><font style="font-family:'Times New Roman','Times','serif';"> The primary efficacy endpoint was defined as the freedom from clinically driven target lesion revascularization or target lesion thrombosis through 6 months.</font></p><a name="footnote-3"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;"><sup style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;">2</sup><font style="font-family:'Times New Roman','Times','serif';"> The primary safety endpoint was the proportion of patients who experienced an adverse event in the 30 days following treatment that negatively affected the access or venous outflow circuit and resulted in reintervention, hospitalization, or death (not including stenosis or thrombosis).</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;The data release of positive findings from the randomized AV fistula arm of the WAVE study marks a major milestone for Merit,&#8221; said Fred P. Lampropoulos, Merit&#8217;s Chairman and Chief Executive Officer. &#8220;This is an important next step in our continued efforts to seek ways to improve care for patients requiring hemodialysis treatment.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Merit WRAPSODY Cell-Impermeable Endoprosthesis is not approved or available for commercial distribution in the United States and may not be approved or available for sale or use in other countries. In the United States, the device is being used under an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA). Findings from the WAVE study expand on results from the first-in-human study (WRAPSODY FIRST) and support the Premarket Approval (PMA) application to the FDA for commercial use in the United States. The device is available in Brazil and in the European Union. For additional information on Merit Medical&#8217;s WAVE study, please visit: https://clinicaltrials.gov/ct2/show/NCT04540302. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Statements contained in this release which are not purely historical, including, without limitation, statements regarding results, outcomes and applications of clinical trials, studies and investigations involving Merit&#8217;s products, safety, efficacy and patient and physician adoption of Merit&#8217;s products, Merit&#8217;s ability to procure and maintain required regulatory approvals for its products, forecasted plans, revenues and other operating and financial measures, or future growth and profit expectations or forecasted economic conditions, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to risks and uncertainties such as those described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 (the &#8220;2023 Annual Report&#8221;) and other filings with the SEC. Such risks and uncertainties include inherent risks and uncertainties related to the safety, efficacy and patient and physician adoption of Merit&#8217;s products, the ability to fully enroll and the final results and outcomes of clinical trials and studies involving the Merit&#8217;s products, the ability to obtain and maintain reimbursement codes for Merit&#8217;s products, Merit&#8217;s ability to procure and maintain required regulatory approvals for its products, disruptions in Merit&#8217;s supply chain, manufacturing or sterilization processes; reduced availability of, and price increases associated with, commodity components and other raw materials; adverse changes in freight, shipping and transportation expenses; negative changes in economic and industry conditions in the United States or other countries, including inflation; risks relating to Merit&#8217;s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; risks associated with Merit&#8217;s ongoing or prospective manufacturing transfers and facility consolidations; fluctuations in interest or foreign currency exchange rates; risks and uncertainties associated with Merit&#8217;s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Office of Inspector General &#8211; Department of Health and Human Services; difficulties, delays and expenditures relating to development, testing and regulatory approval or clearance of Merit&#8217;s products, including the pursuit of approvals under the European Union Medical Device Regulation, and risks that such products may not be developed successfully or approved for commercial use; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit&#8217;s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; restrictions on Merit&#8217;s liquidity or business operations resulting from its debt agreements; infringement of Merit&#8217;s technology or the assertion that Merit&#8217;s technology infringes the rights of other parties; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, including reforms to the procedures for approval or clearance of Merit&#8217;s products by the U.S. Food &amp; Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other jurisdictions; termination of relationships with Merit&#8217;s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit&#8217;s existing or future products obsolete; market acceptance of new products; dependance on distributors to commercialize Merit&#8217;s products in various jurisdictions outside the United </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">States; volatility in the market price of Merit&#8217;s common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; failure to introduce products in a timely fashion; price and product competition; fluctuations in and obsolescence of inventory; and other factors referenced in the 2023 Annual Report and other materials filed with the SEC. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ABOUT MERIT MEDICAL</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRADEMARKS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>mmsi-20240918x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20240918x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# 74# 2(  A$! Q$!_\0
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M/V@/AI874MM<>/?#T4\3%70ZC%E2.HZU#_PT7\+O^B@>'?\ P8Q_XU/MJ?\
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M1D]C7VOKWPK\)ZSX#N?"<V@V*:"ULT*6D<"JL0VX#)@?*PZAASGFN _9'^"
M^"_PNMUOX!'XEUC;>ZF2/FC)'[N#Z(IQ_O%CWKVJX_X]Y?\ </\ *M\+1<:5
MZNLGW[=CQN(<TIULQ<<N]RE3?N\NB<EO/3J^^[23>I^(CIY;LF2VUBN3WP<5
M^FO[ _\ R;EIG_80O?\ T<:_,R?_ (^)O^NC?S-?IG^P/_R;EIG_ &$+W_T<
M:\;+/X_R_P C]:\0?^1/'_''\I'T5117B_[67QJ'P7^%-W<V<P3Q%JI-CI:]
MT<CYYOI&N3_O;1WKZ:I4C2@YRV1_/V"PE7'XB&%H*\INR_KLMWY'QU^W'\;3
M\2OB0WAC3;DR>'/#CM 0C?)<7G260]CL^X/<.1UK+_84U6[TW]I#1+>VF>*"
M_M+J"ZC4X65%A:10P[X9%(]*\ Y.26+,>2S'))]2?6M_P1XUU+X?:ZVLZ1)Y
M&HBTN+6*?O%YT31LZ_[05B1[XKXWV[E75:7>Y_5$LFIT<FGE6&2^!Q5^K:W?
MSU/8/VT/C6?BS\4IM,T^X\WPUX>9K2U"ME)IP<33>AY&Q3Z+D?>-?/S,J#+$
M*/4TH 4 #H*[;X/?$6W^%?CF#Q#=:!:^)H8H)83IUXP$;%P &R589&/2LYS=
M:HY3>YZ&&PL<JP,</A(<W)'172YGZO1-O=^9PWVB'_GHG_?0KZ1^$%UXH\-_
MLC?&#48)KJQT*]DLK>QD!95=WE$=T8CZ%&121U/N#741_MTZ"'7?\%_#^S/S
M!9H\X]OW%>M_'3XHZ%\7_P!B;6_$/AZ!K.R9[:WDL74*UK*ES$&B(7CC(((X
M((/>NVC2IKFE"I=I/HUT/C<US/'U)8;#8K!<D)U::YG*,DK23M9;-VZ]+GYW
M*JHH   '0 =*9]HA_P">B?\ ?0JW8#.H6@(R#/&,'O\ ,*^]/C7^U;\//A=X
MYOO"^E?#73/$=SIS^5>W+10V\22XR8U_=L6(R 3P,Y'.*Y*5*,XN4Y<J1]3F
M.98C"5J=##8=UI34GI)1LHVW;TUN?#?A#Q?K/@'Q#:Z[X=U&72M5MF#1W$!Q
MN']UQT=3T*G@BOM3]I#XV2_%+]C'0_$-BYL)-8U."QU2VA8X#H)#+%_NEXU.
M.ZD9KXL\8Z[!XH\6:QK%KIEOHUO?W4ES'IUK_JK<,<[%X' ^@^@Z5[EJFBWF
MD_L$Z3/=(T<>H^,3=VP;O%Y4D88>Q:-C6U"<HQJ03T:9Y6<X.A6KX'%U8)5%
M4BNE]4VX^=FKKM;3<^=#A5R< #]*:LT;D!71B>P(KO/@1;Q7?QM\!03Q)/!)
MK=HCQ2J&5U,@R"#P1[5^@?[8OA#0=+_9R\87-GHFFVERB6^R:"TC1US<Q X8
M#(XXJ:.&=6G.HG\)OFG$,,LQ^'P$J;DZS2O>UKRMM;4_,/ J(W$..9$_[Z%7
M=. ;4K($9!N(P0>_SBOV9_X5[X65PP\-:.&!R"+"+(_\=JL+A'BKV=K&'$7$
ML.'G24Z3GSWV=K6MY/N?-W['/B&]^%W[+.K>)/%[3VOA^RN+B]L$G!#_ &;:
MN!&#V>7<$'<MQU%>H_!'X8%=%N_%_C/3+:Z\<>*'-]J#740E:SB;_4V2%L[4
MBCVJ0.K;B:H>-%'Q@^,NF>"8@)/"OA PZSKV!\D]X>;*T/8A<&9ATXC'>O;J
M^CH4EI%ZJ.B]>K^6R^9^#9MCY3E.LER5,0^>272.\8_/XWW]UGS+8>,;+]G_
M %CXRZ;I%GOL+2\TV70?#\/"OJ%]"?W$*C[JO*H8J.%!<UZ9\)O@GIG@OPPC
M:[966N>+M18WNMZQ<VZR275TYW/AF!(12=J+T"J.*Y32/@W<ZW^U1XI\=:LC
M_P!B:=%9KI=L_P#JYKW[-M>XQW,:.4!]9&[BO>:*%.[;DM$VE][_ .&]/4C-
M,;&,80H3O*<82F^[Y(KEOUL[R?>3UUB8X\&Z!_T ],_\!(_\*\Z_:"\)?#ZV
M^$WB&[\2:?ING06UK)+;7D420W$-R%)B:!U 82[]NT+R3@<YK@/B5^S-X@\6
M_%3Q-XECTKPAK]CJC6YMTUZ\OXI;81PK&R@087#%2>]8=A\-[3X$Z_I/B3QG
M\,?",NAK=Q0G7-"N[JY?297<)'-)#<Y&S<R@NARN0:BI4DTXRA9=W^>WZG;@
M\)1C*E6I8J4IZ/ECRIMV3Y4W.][Z?"VWLGHCH_@#H4WC[QYXDUGX@6$6J^*-
M%TW1]-C6_C$@LR]C'//L5LA7>20EB!G@#H*]XF\(^&5PDVBZ2-W17M(N?S%>
M>_"+_DM'QL_["FG?^D$58'Q4\!Z!\1OVE?!VD^)=+AUC31X9U&<6\^=HD%Q;
M@,,$<@,1^-.'[NEHKN[6OK8PQ5\9C^64W""IQE:*O9*FI62NEOY];G<>)?V=
M/AMXJ/F7?@_3+:['*7VFP_8[F,_WEEAVL#^-<?<:KXF_9QO;637-9N_&'PPG
ME2WDU34</J.@LS;4::0#]_;DD N1O3())%0>+_A7>_ W1[OQ?\,;[48(-+0W
M=_X1N[R2YL;^V09E6(2%FAE"@E60X) !!!KUZ)M&^)_@5&9%O] U_3@VQQQ+
M!-'T(]U:K4;MI+EFNVS_ ,T82Q$J=.#J5'6P\G9J7Q1?6UV^65M4XMI[.Z31
MY1\*?".C_$/Q_P#$OQ9XDT^UUW5+77YM"L6OXEFCM+.&.(JD2L"%W,[,Q'+$
MUE:+K_A_]GKXE?%&T!_LKP1:Z58:\NFVZDI!=3/-$Z6\8Z&5HX\(O!<\8S3O
MV(-*N]!^'?B[2[^>2YO-/\5WUG)-*<L_E+%&"3]%%96O>#3XU_;CACNF+Z/I
M/A^TUB>U/W)IXY9DMMP[[&E9Q[J*YE?V5.<5[S?YW/9FH/'8O"UYMT806VUH
M.%N5;)O9/I?U.JTOX5:_\;%37/BK-<V6DSGS++P%97#16UO'_";UT(:>8CDK
MD(IXP:],TKX5^#-#LEL]/\):)9VJC BATZ)5Q[_+S6+\:OB!J7@G0=-LO#UO
M#=^+?$%\FE:1%<Y\I)G!9II,<E(T5W('7:!WKFK3]EOP_J4'VGQAK?B+QCK\
M@S-J=SJ]Q;!7[^3%"ZI$H[ #CU-=2BHR<81YGU;_ ,]?NV/$E6G6HQJXBLZ5
M-M\D(*^V[4;Q5NCDWS2=]VFRWXR_9N\*WIGUGPK%_P (!XLB1GM]:\/XM<.!
MP)HUQ'*F?O*ZG(SR*Y%_C;XB\=_"/X=V.A/%I_C_ ,=1>4+B)=Z6$,>1=WH4
M_P *@?(#U:1!S6UJ?P!U6+2+O2[SXN>*$\#>6QN=/N6A:X$&/GC-\5\T1[<@
M\YQD;JB_9N\.6^NS7_Q&%B-/T^_MTTGPO8;2HLM$@.(MH/0S,#*?;9Z5BXRY
M^6,>6^_^>GW7WU\CT(U:*PKKUZOMO9M.-T]&T[0?,M;OWG'6*4&D_>.T\%?
M7P-X&T\P6F@6E_>2_-=:IJD2W5Y=N?O/+*X+,2>?3T K@OC-\/M-^$&G7'Q3
M\"V$/A[5]$*7.JV6G((;;5K$,!/%-$N%+A"75\;@R]>:9\=/C+JVC?%CX?\
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MK],_V!_^3<M,_P"PA>_^CC7YF3$-/*0<@NQ!'?DU^F?[ _\ R;EIG_80O?\
MT<:\'+/X_P O\C]G\0/^1/'_ !Q_*1]$.ZQ(SNP1%!+,QP .Y-?E!^U-\:&^
M-?Q6O;^UE+^']-S8Z6O9HU/S2_61AG_="#M7VI^W7\4;WX>_!S^S=-+Q7OB2
M<Z:;E3@Q0["TN#ZLHV_1B>U?F[X;\.W_ (MU_3="TB#[1J6H3I:VT(Z%V.!G
MT ZD]@":Z,SKN4E0C\_T/"X RF%*E/-Z_FH^27Q2_3T3[D3Z/>1Z-#JSV[+I
MTUP]K'.?NO*BJSJ/7 =<_P"\*IU];_MJ_#;3_A'\+OA%X6TX!HK'[<)9\8,\
MS+"9)#[LQ)]A@=J^7_"'A34O'7BG2O#VD1>=J>IW"VT"GH"3RS>BJ,L3Z UY
M%6DZ53V;WT_%'Z?EF:4\QP7UY:0;EO\ RQDU=_)7?8IS:3>6^E6NI26[I8W4
MLD,$S#Y9'CV[P/7;O7/UK;^'/PXUWXK^*8O#OAR"&YU66)YDCGF$2E4 +?,>
M.]?0_P"W%X T_P"%WA[X3>%]*4_8M.L+R(2$<RONA+R'_:9B6/UKYP\$^.M=
M^''B"/7/#>H/I>JQQO$MRB(Y"L,,,,".<>E.=-4:O)/I:YG@L?4S7+OK>$LI
M2YN7FO;2346[:]$W8]D3]@[XQ,Z@Z/I: G&YM4CP/<X&:]S^)'P6?X$_L->(
M_#US>)?ZG-=07M[/""(_->XA&U,\[555&3UP3@9Q7S=_PV'\8_\ H>+G_P !
M+;_XW6+XQ_:1^)/Q \.W6A>(/%,^I:3=;3-;/;PH'VL&7E4!X90>O:NI5<-3
MC+D4KM-:V/FZN6\0XZM0>,JTE3ISC-J/,F^5WZI_+5>9YY8'&H6A])X__0A7
MO?[;GPHN/AW\9KW6$5GT?Q.SZC;RGHLW'GQD^H8AA[./2O ['_C_ +3_ *[Q
M_P#H0K]9/VF?@Y'\:_A/J.C1(O\ ;5J/MNERMP5N$!PN>P<%D/\ O9[4L-0]
MO2J);JS7XFN?YPLGS/ U*C_=SYXR\DW#7Y/7TN?F?\#O#7ACQC\5?#VB>,+R
M>QT.^N!"\ENP4O(?]7&S'[BNV%+#D9'3J/MC]O\ TFST+]G?0M-T^VCL["TU
MFU@@MX5VI&BPS!5 ] !7YWR1R02O'*CPS1L5=&&UD8'!!]""/S%=IXR^-GCO
MXAZ)%I'B7Q/>ZSIL4JS);W.S =00K9"@D@,>I[UG2KQITITVM7U.[,\FQ&.S
M/"8ZG5]RD[N+O]ZLMWL[]D3_   _Y+K\/?\ L.VG_HT5^BO[:G_)M'C/_<MO
M_2F*OSJ^ '/QU^'O_8=M/_1HK]%OVU/^39_&?^Y;?^E,5=V#_P!VK?UT/C>+
M/^2ARWUC_P"EH_+33?\ D)V/_7Q%_P"ABOV+^+'Q#MOA;X$U3Q#-";N>!1%9
MV2??N[IR$AA4=R[LH^F3VK\=--_Y"EC_ -?$7_H8K]4=2MW^)_[1R:==X&@?
M#^V@U'[,Q_X^=2N5<0R$?W8HE<C_ &I,]J672<8S4=W9+\?RW-..Z-.K7PLZ
MW\."G*7FDX*W_;S:C?I>_0ZCX(_#RX^'?@>.'59EN_$VIS/JFMWH_P"6][+\
MTF#_ '5X1?\ 905)\)/BE:?%K3_$.IZ<%.F6.LSZ7:S*<^>D2H#)]&<OCVQ6
M%^T'XEU#^Q=+\#>'IS!XH\93MIMO,GWK.U S=W7_ &SBSC_:=*R?V4O#]CX3
M\-^.M#TR'[/IVF>+]0M+>+.=L:"(*,^N!7LJ7+4C2ALOS_K5^I^4U*'M\%6S
M#$/]Y-IQ7]V]F_2_NQ[<LEV/:;N[AL+2:ZN94@MX$:2660X5$ R6)[  $UQ_
MP=^),/Q;\"6_BFUA\BQO+FY6U4]6ACG>-&/NRH&([9Q7'?'&]G\>^(="^$VF
M2.IUH?;_ !!/$<&VTB-AO3(Z-.^(A[%SVI_[),45O\#].@@18HH=1U.)(EZ1
MA;Z<!?;  %5[5RK\BVL_OT_*YA+ TZ65O$S_ (CE&R[1:GK_ -O..GDK]2QK
MWQ[NK#QMKWAK1OA_XC\4SZ(T*7=UIAMA$K2Q+(H_>2J?NMZ5S7C2[\<?'[2!
MX-7P%J7@KP_?31'6-7UZX@WBV217:*"*)W+2/M"[C@*"3R<5UNO_ +/NGZSX
MPUKQ):>+O%WAV]U=HGO(M$U-;>&1HXQ&AV^63G:H[U6_X9X;_HJ/Q'_\'J__
M !JLI1K2NI;:]MOSV/0HU\MH*G4HVC.*B[M3;4DE=VYN5VE=K2VUT,^$?_):
M/C9_V%-._P#2"*DUX_\ &5_@_P#[%34O_2FVKJ/AI\)=.^&$VN7%KJVLZW>Z
MS/'<7EYK=T+B9V2,1K\P5> H _"O%_VB/%^L^%_VBOA]:>&VMXO$.NZ1=:-9
M75VN^*T:6Y@+3LG\>Q8W(7N<4IWI4DY+[5_OE<K"J./S"4,.[KV3C=Z?#2Y6
MWV6C?H>T?&OQS8_#WX9Z[JEX?,E>W>ULK1>9+RZD!2&%%ZLS,0,#MD] :L?!
MSPG<^!/A3X0\/7AW7FF:5;6T^#D"18P& ]@<BN?\)? '2M%\0V?B3Q!K6L>.
MO$UF#]FU#7[@2):,?O-! H6.(GU"Y'K5?XV?$6\MQ'X!\'R+<_$#7XC% J?,
M-+MVXDOI\?<1 3M!Y9]H&>:V;<6ZM16Z)?UU9YT:<*T8Y?A)<UWS2DU9:*U^
MZC%7;;LW?96UQ/V3-8@\0Z+\1]3MB&M[OQOJDL;#H5)CP?QQFJ^FZY;V'[;>
MMZ;,ZI-J/@ZV: 'JQBN)"P'X.3^%3?LD>%[/P1X;\=^'=/W_ &+2O%EW9Q&1
MLN52& 98^IZ_C7'_ !*\$ZMXH_:0\2:QX7:-?&7AK0M*U+2?-?;'.WG72RVT
MA[+-'E,]CM/:N6\HT:;MK?\ SN>^X4*N98V#E:#A9-]+N'*WV5[7[*YZ!^T-
M,WA34_A_X_EC>72/"^KNVJ;%+&"TN(7@>? YQ&61CZ+N/:O7[*]M]2LX;NTG
MCNK6=!)%/"X=)%(R&5AP01W%<A\-OB;H7Q>\.33VB&*ZA)M=5T2_0"YL9L8>
M">,].XSC##D9%<I_PS!X:T^68>'->\5^#+"9B[Z9X>UJ2WM,GKMB.X1Y]$VB
MNI<UW4IZJ1\].-)PCA<:W3J4KI:733;=GJFFFVTU=-/I:[J?'35'^(>N:7\(
M='N3]HUC%UXCFMV^:QTE2"ZL1]UISB)1UP7/05[';VD6F:?';65ND<-O$(X+
M=/D154851Z#  KF/ GPU\+?"/1[U-&M5L8YF-S?ZC>3M+/<,!S)//(2S8&>6
M.!SC%<5'^U7X/O0\NFZ7XKUJQWLL6H:9X=N[BVG )&Z.14PZY!P1P:$U3;E5
M:3?Y#G2J8V$:& IRE3I[NV\I;MVNE=))*[T7>YY=X=^%GQ3O]4TUM?\ ".G0
M7UWXSM?$^L:\FM)*6CA<B.%(0F=D<6U%&[L3W->W?M)#/[/_ ,1?^P#>?^BF
MK'MOVHO"DNIZ;97.D^*M*.H7<5C#<:GX?N;:#S9&"(K2.H5<D@<FO2/&'A:R
M\;^%=7\/:EYO]GZI:R6=QY+;7\MU*MM.#@X-13IP]G*-.5[G;C,7BEB\/6QM
M'V:BTTDGLFKVNWLDDDK)*RL-\%Y/@W03_P!.%O\ ^BUK9KQZW_9JM+6".&'X
MB?$2.&-0B1IXB<*J@8  V] *Y[QQX?UW]GNRLO&.D>-?$/B'1K>^MK;5]%\2
M7@O%GMYIDBWPN5#1RH75A@X8 @BM/:3IQO*.B\SA6"P^+K<F'KWG)Z)Q:NWL
MKZZO9=+[M+4^@J***ZCP#Y:_X*+?\D.TK_L/0?\ HF:OSJLKVXTV\M[RTGDM
M;NWD6:&>%BKQNIRK*1T((!S7Z\?';X.:?\=/A[=>&;ZZDL',J7-K>1KN,$R9
MVL5XW#!8$9&0QY!YKX^;_@FSXNW''C/1",\$VLP_K7SN.PM:I6YX1NC]RX.X
MARO Y9]5QE50DI/1IZI^B9XCXH_:1\<^+M%O--N[K3[3^T%5-0OM-TZ*UO+]
M1R!-,@#,,@9QC/>M;6OVOOBKX@\%2^&+SQ&K64T/V>:ZCMU2[FC(P5:4<\C@
MD $\\\UZO_P[9\7_ /0YZ'_X"S?XT?\ #MGQ?_T.>A_^ LW^-<GL,9KH]?/_
M ()]+_:_"=HKFI^Z[KW'H^Z]WR7W+L>-P?M0_$"WT2.Q2]T_[;':_88]=.G1
M'5$@V[?+%SC=TXS][WSS5WPQ^U]\4_"'@N+PQI^OQ_88(O(M[FXMEENK>/&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>mmsi-20240918xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20240918xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !F G8# 2(  A$! Q$!_\0
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MOBN"0QL5888<$'M7C5\1-3:B[6/U'*,FPDL)"K7AS.2OK^1]UI_P52^([_\
M,J^&/^^;C_XY4R?\%2_B.W_,K>&?^^;C_P".5\06\H/>K\,F:XWB:R^T?2PR
M3+'_ ,N5^/\ F?:H_P""HWQ&/_,K>&?^^;C_ ..4X?\ !43XBG_F5_#7_?-Q
M_P#'*^,T((J50*S^M5OYCKCD&5O_ )<+\?\ ,^RA_P %0?B*?^97\-?]\S__
M !RG#_@I_P#$4G_D6/#7_?,__P <KXX J08I?6JW\QLN'LK?_+A?C_F?8H_X
M*>_$3_H6/#7_ 'S/_P#'*>/^"G/Q#_Z%GPW_ -\S_P#QROCQ1@>]. S4_6ZW
M\QJN'<J_Y\+\?\S[#_X><?$,C_D6/#?_ 'S/_P#'*4?\%-OB'_T+/AO_ +YG
M_P#CE?'X%. I?6Z_\QJN&\I_Z!U^/^9]@#_@IK\0_P#H6/#?_?,__P <I1_P
M4T^(1_YEGPW_ -\S_P#QROD #-/"T?6Z_P#,:KAK*?\ H'7X_P"9]>C_ (*8
M_$(_\RSX<_[YG_\ CE.'_!3#XA?]"SX<_P"^9_\ XY7R&%XIP6I^N5_YC1<,
MY0_^8=?C_F?7G_#R_P"(/_0L^'/^^9__ (Y2_P##R[X@_P#0M>'/^^9__CE?
M(F,TX"I^N5_YS5<,9/\ ] \?Q_S/KG_AY=\0?^A9\.?]\S__ !RE_P"'EGQ!
M_P"A:\.?]\S_ /QROD8"G8H^N5_YS1<+Y/\ ] \?Q_S/KC_AY7\0/^A:\._]
M\S__ !RC_AY5\0/^A:\._P#?,_\ \<KY)VTNRE]=K_SLK_5;)O\ H&C^/^9]
M;#_@I3\0?^A:\._]\S__ !RE_P"'E'Q!_P"A;\._]\S_ /QRODH+2[32^NXC
M^<M<*Y-_T#1_'_,^M/\ AY1\0?\ H6_#G_?,_P#\<I?^'D_Q!_Z%KP[_ -\S
M_P#QRODL"@K[4OKN(_G92X4R;_H&C^/^9]:?\/)_B!_T+7AW_OF?_P".4?\
M#R?X@?\ 0M^'?^^9_P#XY7R9MHV^U+Z[B/YV/_53)O\ H&C^/^9]9_\ #R?X
M@_\ 0M^'?^^9_P#XY6==_P#!37XE6C?-X6\-,AZ,%N,?^C*^7=E(\0=2K $'
MJ#5+'5UO(RJ<(Y1)>[ATG\_\SZ<'_!4'XB'_ )E?PU_WS<?_ !RGC_@I]\1#
M_P RQX:_[YG_ /CE?)-[H[1DO!DKW3N/I6>#6ZQE9[2/'GPSEM*7+/#K\?\
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MQ _Z%OP[_P!\S_\ QROD-E:-L."I]",4!JT^N8C^<Y_]6<FV>&C^/^9]>_\
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MN]-W#S5T^:6&8+W*ERRY]B.?45\7:KH^HZ(T2ZCI]WI[3)YD2W<#Q%U_O+N
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M<^RO%<WL:Z?*FWNM%N]4MO(\? S3L5]G#_@F5XF _P"1WTG_ , Y?_BJ4?\
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ML@0DG@,<*3_%CFG:#\#]6UGPQKNJS74.G7&DR3126%PI$A>(9D4\_*1]#ZG
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MGD#->9_$KXO>$?'^H7NL_P#"':A%X@D:,P3WFL^?:P*C#;$+<1*/*"@J$!
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MZ:R6M]U?N>AVGA;4_@9X6^*NO6>K+?Z\MOI4>E>([-F#M97[-(UU&Q^9'D1
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MY1DP. 1*C9&>#5QA33LW_5[')7Q>-E2<HQLUMHWK[-RO]^B5M_,^>=<TB_\
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M7.@/G=I0O9!:G)R1Y0.W&><>M*,HQ*KT*]>/1.S7R=M?73;\3T+5O ?A/4O
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MA]GHHKDQ5*#DI6U/HN'L?B8494E/W8[+32X@_P""?WQ&_P"@OX7_ / NY_\
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M_B4!_P ACPK_ .!ES_\ (]%%=#IP['A1QV(_F_!?Y$J_\$_/B2N/^)QX6_\
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MF/\ L"_$5NFK^&/_  +N?_D>BBG[*'8SEC\3_-^"_P B"3]@#XCL.-8\+_\
M@9<__(].M?\ @GQ\0&.Z?5_#+>BK=W&/Q_<444W3C;8SIX[$2GK+\%_D:7_#
M!?Q 4 #5?#( Z 75Q_\ &*3_ (8-^(7_ $%O#/\ X%W'_P 8HHJ/90['H/,<
M5_/^"_R$/[!GQ"/_ #%O#/\ X%W'_P CTW_A@KXA_P#06\,_^!=Q_P#(]%%'
MLH=C)YCBOY_P7^0T_L$_$/\ Z"_AG_P+N/\ Y'IC?L#?$//_ "%_#'_@7<?_
M "/1135*'8S>88G^?\%_D,/[ GQ$/_,7\,?^!=Q_\CUJ^%?^"=7CK7M;M[2^
M\1>'K&T8YEFMY)YI%7OM0Q("?JPHHK2-&#DDT<>(S+%0HRE&>J3Z+_(_1OX1
M_"S1?@SX TSPGH*/]BLE.Z:7F2>1CEY'/JQY]N!VHHHKZ))15D?B=2I.K-U*
&CNWJV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>mmsi-20240918xex99d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20240918xex99d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !F G8# 2(  A$! Q$!_\0
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MOBN"0QL5888<$'M7C5\1-3:B[6/U'*,FPDL)"K7AS.2OK^1]UI_P52^([_\
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M_P#QRODL"@K[4OKN(_G92X4R;_H&C^/^9]:?\/)_B!_T+7AW_OF?_P".4?\
M#R?X@?\ 0M^'?^^9_P#XY7R9MHV^U+Z[B/YV/_53)O\ H&C^/^9]9_\ #R?X
M@_\ 0M^'?^^9_P#XY6==_P#!37XE6C?-X6\-,AZ,%N,?^C*^7=E(\0=2K $'
MJ#5+'5UO(RJ<(Y1)>[ATG\_\SZ<'_!4'XB'_ )E?PU_WS<?_ !RGC_@I]\1#
M_P RQX:_[YG_ /CE?)-[H[1DO!DKW3N/I6>#6ZQE9[2/'GPSEM*7+/#K\?\
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MQ _Z%OP[_P!\S_\ QROD-E:-L."I]",4!JT^N8C^<Y_]6<FV>&C^/^9]>_\
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MN]-W#S5T^:6&8+W*ERRY]B.?45\7:KH^HZ(T2ZCI]WI[3)YD2W<#Q%U_O+N
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M<^RO%<WL:Z?*FWNM%N]4MO(\? S3L5]G#_@F5XF _P"1WTG_ , Y?_BJ4?\
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ML@0DG@,<*3_%CFG:#\#]6UGPQKNJS74.G7&DR3126%PI$A>(9D4\_*1]#ZG
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MGD#->9_$KXO>$?'^H7NL_P#"':A%X@D:,P3WFL^?:P*C#;$+<1*/*"@J$!
M-"?'#PYH$][K/A3X>VGASQ9=020#4$U"6:VLO,4I(]M;L/D8JS ;F8)GBM?:
MJ]N;3YW9YRP$^13]DU4NVO@Y8M\O2[TT5VM7J[*Z+/[/_C?7+GQ!X>\/GXE#
MX?Z!IUT+N,%FBCN':1=R-L $C,.!YQV@<9 K@_C*K1?%?QBKZ.WA]O[5N&_L
MML9MLR$A/EX[]N.>.*VO#OQ.\)6WA_2+'Q+\.[/7[W1PRVMY;7KV7VB,L7"7
M2HI\X D_-PQ'!.*P?%7Q%C\<7GBW5]>TF.\\2ZY>1W<.I1S-&MD QWHL0X8,
MNU1D\!:Q;3@HW_/^ON/3A"<,5*JJ=DU;[/\ -NK.[ZM\VJZ;L[3PUK=_>?LJ
M>/\ 3I[R:;3[+6]*:VMG<F.$N9RY4=!N(!/K6W\'=.\*_#'X?1>._$WB"XT'
MQ)KTDUGX<GL],_M"2QBC.R>\$9= 'W$HC$DKAB%)QCR;2?'QTKX:>)?"/V,2
MKK-[9W9N_,QY7D>9\NW'.[S.N>,5N^'?BUH9\$Z;X7\9^#U\56.D32S:7<6^
MH/8W%N)6#20LRA@\;,-V, @DX/-:1E&Z;W2_7_(XL10JN-2,4^64[NUKM<J[
MZ:R6M]U?N>AVGA;4_@9X6^*NO6>K+?Z\MOI4>E>([-F#M97[-(UU&Q^9'D1
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MY1DP. 1*C9&>#5QA33LW_5[')7Q>-E2<HQLUMHWK[-RO]^B5M_,^>=<TB_\
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M7.@/G=I0O9!:G)R1Y0.W&><>M*,HQ*KT*]>/1.S7R=M?73;\3T+5O ?A/4O
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MA]GHHKDQ5*#DI6U/HN'L?B8494E/W8[+32X@_P""?WQ&_P"@OX7_ / NY_\
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M_B4!_P ACPK_ .!ES_\ (]%%=#IP['A1QV(_F_!?Y$J_\$_/B2N/^)QX6_\
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MF/\ L"_$5NFK^&/_  +N?_D>BBG[*'8SEC\3_-^"_P B"3]@#XCL.-8\+_\
M@9<__(].M?\ @GQ\0&.Z?5_#+>BK=W&/Q_<444W3C;8SIX[$2GK+\%_D:7_#
M!?Q 4 #5?#( Z 75Q_\ &*3_ (8-^(7_ $%O#/\ X%W'_P 8HHJ/90['H/,<
M5_/^"_R$/[!GQ"/_ #%O#/\ X%W'_P CTW_A@KXA_P#06\,_^!=Q_P#(]%%'
MLH=C)YCBOY_P7^0T_L$_$/\ Z"_AG_P+N/\ Y'IC?L#?$//_ "%_#'_@7<?_
M "/1135*'8S>88G^?\%_D,/[ GQ$/_,7\,?^!=Q_\CUJ^%?^"=7CK7M;M[2^
M\1>'K&T8YEFMY)YI%7OM0Q("?JPHHK2-&#DDT<>(S+%0HRE&>J3Z+_(_1OX1
M_"S1?@SX TSPGH*/]BLE.Z:7F2>1CEY'/JQY]N!VHHHKZ))15D?B=2I.K-U*
&CNWJV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mmsi-20240918.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/18/2024 7:37:50 PM-->
<!--Modified on: 9/18/2024 7:37:50 PM-->
<xsd:schema targetNamespace="http://www.meritmedical.com/20240918" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mmsi="http://www.meritmedical.com/20240918" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20240918_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20240918_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>mmsi-20240918_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/18/2024 7:37:50 PM-->
<!--Modified on: 9/18/2024 7:37:50 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>mmsi-20240918_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/18/2024 7:37:50 PM-->
<!--Modified on: 9/18/2024 7:37:50 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mmsi-20240918.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638622850708101902" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638622850708101902" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638622850708101902" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638622850708101902" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638622850708101902" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638622850708101902" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638622850708101902" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638622850708101902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638622850708101902" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638622850708111916" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638622850708111916" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638622850708111916" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638622850708111916" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638622850708111916" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638622850708111916" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638622850708111916" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638622850708111916" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638622850708111916" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638622850708111916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638622850708111916" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638622850708121889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638622850708121889" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638622850708121889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638622850708121889" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638622850708121889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638622850708121889" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638622850708121889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638622850708121889" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46092802825696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 16,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-18592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merit Medical Systems,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0447695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West Merit Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Jordan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">253-1600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MMSI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000856982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-KG%Z991L C; >ZOI33O#;O3K7ZHF/P+4$L#!!0    ( #*#,EF?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( #*#,ED'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ ,H,R65F])?CO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ ,H,R69E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  R
M@S)9Q"RXK$\$  "T$   &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ ,H,R69^@&_"Q @  X@P   T
M         ( !DPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  R@S)9EXJ[
M',     3 @  "P              @ %O#P  7W)E;',O+G)E;'-02P$"% ,4
M    "  R@S)9'#AEZC\!   \ @  #P              @ %8$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ ,H,R620>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ ,H,R6660>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mmsi-20240918x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mmsi-20240918.xsd</File>
    <File>mmsi-20240918_lab.xml</File>
    <File>mmsi-20240918_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="mmsi-20240918x8k.htm">mmsi-20240918x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mmsi-20240918x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mmsi-20240918x8k.htm": {
   "nsprefix": "mmsi",
   "nsuri": "http://www.meritmedical.com/20240918",
   "dts": {
    "schema": {
     "local": [
      "mmsi-20240918.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mmsi-20240918_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mmsi-20240918_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mmsi-20240918x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20240918x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20240918x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000856982-24-000087-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000856982-24-000087-xbrl.zip
M4$L#!!0    ( #*#,ED>"+>JE ,  .,,   1    ;6US:2TR,#(T,#DQ."YX
M<V2U5EUSTS@4?=\9_H/(N[^2+269M@Q=V!EFVH4I,-,W1I%O$H$M&4DFZ;_?
M*\5R(L=V"P-/376.CH[NEWSQ:E<6Y <HS:6XG&1Q.B$@F,RY6%].:AU1S3B?
MO+IZ]M?%\RBZO[Z[(;ED=0G"$*: &LC)EIL-^22KB@IR"TKQHB#7BN=K("1+
MX_,XC3,218W&-=6X1PKBQ*9QUB+_-'I2+,@\R5XFTW3Z-SE?S,X79RGY<-L2
M;]'?BC_*W.E\H=D&2DH,56LP_]$2=$497$XVQE2+)-ENMW$)BIL2<LYH$3-9
M.K%TGKV<$&J,XLO:P+]2E6]@1>O"8%C$]YH6S@%&JP ;C(!P!&-XA5Z@D^#(
M[2R6:HT'I5ER?WOST9GTY!QX2]XM51%K8/%:_D@0<-X\$=.SIK1JR2NJETZW
M 0*R5B8R#Q7H4WH+==65+/KX'@GH"E;!%9WSYI(O$D3;6""0F_"&#>\LV8.>
MRFJEL!H?^L/AT<#&KAAT,4ON;[CXYIF"<J;[E1UT$KV!:+10L(')6A@UY'P/
MAN$V:M#Y/$'TR$JOB4"MP(N.!,+"2^Q#3X<=V_1;M4@GP%WIIIBS^7R>.+1U
MREF_* +=4ALH38\$= %K.R=&PF7SD32TUHVIU( =1((#GM#VOJ_YXWT=<:$-
M%0R..X"/9*?+!U&7T[Z&F::8'P-"\V4!D:6!H@8GN8ZF=I(W\\2H3GB#(Q%.
M+&SUIE$ZBV;981)5"MA38GU@'I)D'D^0.?(XPLX/U<^.QDS84[ *Z]1.$MX[
M9E[LQPSWU++LI''D16B&W:[J=X% .#?$UX&:$U_[9GD$R^%Y;L'])GS="''O
M&Q5"&I=SM^97JXJ+E6R6<-&VY<(&_1-FFM@?G^_>C=_9I>A-\];[OZ]%_E88
M;A[>H;PJW<$3PK$^GL1L#7E+.:RXX,Y^BIE.242\P/%/*G*R5R-'<A=)5Z,K
M7^.GQGMQY7YC@6K4<COM.]#L;BAC.S$BK"Y^8>/!V?"^9M7GII,R/ZCO8$7<
M;%W85KV<:%Y6A1T0;FWC'E];QI&OU"]XW1A+RU.L_LC(<<GN1J@YV$M0Q4Y4
M3F8_BL@*E.$XLP^O3/+;KE70Y<]>"[= \6?N<Y%TNZU9";O2]21>32I#1.\W
MZ- #L/]\O9',B8ULL?^U#TUDEZ)LBJ,\QJ.]WW$;_1]B3S3@-]B3SW[RS-//
MV[Y#]1#=_G#U<3AVGX2]RM7_4$L#!!0    ( #*#,EGEJ/"8:@4  .X[   5
M    ;6US:2TR,#(T,#DQ.%]L86(N>&ULU9OA;^(V&,:_3]K_\![[LDD70NA.
M75';4\OUIFKTB@ZFG39-IY 8L!9LY)@"__W929R2U Y<Z"+SI9?R/GG\O.9W
MC@/IY?O-(H(GQ&),R57+:W=:@$A 0TQF5ZU5[/AQ@''K_?6//UR^<9POMY\'
M$-)@M4"$0\"0SU$(:\SG,*;+I4_@ 3&&HPAN&0YG",#KM,_;G;8'CI-YW/JQ
M.(<22,RZ;2^O]#,_2GIPX7J_N=U.]U<X[YV=]]YU8/B0"Q]$OBG>JXPP^:\G
M?TS$D" :)7%O$^.KUISS9<]UU^MU>WW6IFPFSN]X[I>'P2B8HX7O8!)SGP2H
M!4+?BY,7!S3P>3)+.Z=O)BQ2!F=N/I91(7]SE,R1+SE>USGSVILX;&419?F
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M/H\\$$?R+V"SE[*SK[\!4$L#!!0    ( #*#,EGX/[OP=00  /LE   5
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M:H?P.8*+ NV/VINA^67*6NNR\OC!SO^S1?T=RMYI@W=_#/GP-U!+ P04
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MU5RBHZBYQSH+EZFP"V^32+26K&B,E _O>HR:']X-6$ )-L^PF]"Z?;]EN$X
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M,2YJ<&>U>7=04]^W[T&J=*1*50%I DJOB<@7$! 0D%XB8@%"D1YJ% 24*EU
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MS(8\:ZH/_D![KKL[IB,9WI4-2ST_,OHG>2_=2SJ&5+W!8%QMYQC>O^=>_TI
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M:-'*<"2M:/Z;_Y\/F#C[WP!02P,$%     @ ,H,R699OOM.-*P  CG4! !@
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M:6#)JW>G\:4 [E'/7<Z6R'7RNV!?91#(6,9)@QU_.&JPT[/CYSVK/X#*$QG
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MZ/\=LD^?SD_? #U]300-@XX;"AZEPX K()H(AC&9[@;0,N1HP>,DH^TOT 5
M8Z9A*> ;9Z$ !I!8&\@XJ>2Q \_<A]3YKY409 YW%#@[4? X,#P+N!ZR((FU
MA %SAVAF=/QF)U?R+;L@XL<8F$_C(/J@CHDC4]PI YR(C:1#E60#5.;@,O:
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M$>4.>!>&CC@](2%CH@]LG+9,^&Q5^.\9;+TIJ'N>C3#2L.0T[N$R#^1X8IQ
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M3KO6?%O%MW4L?SFQ_(I-\76@:D5UQ/6!_1>M(_86"635@?^G#/R_:+[=7R@
M6^O;)PS OFB^W6T=U(F#FF^?'=_N7>E+K/6!6?<ZQYWQ.+S=V>T/M5KN:"S'
MJWC3M2NX*'N43U3+ES](HD0=_K1YL+6_?=!=E!AV>Y@L[;)9O(N9/3>E+BLW
MW3"[Y>;!IHD*;+/=G=V01S]WNDR)?B2"5+-/T$2*OW;VNIKULRAJ3M$Y)7^V
M+V-X2/*(#>SS#396XE(FF8ZF3,:I2L(L@/:3F!UE ^ )UFG0LW!CE&F6#@4\
MD?P%?>6I,XVY,[S @[\S:?9/XT]<:P$7R4T^3I+O,+80%\[\PKUV@BC1P)L,
MYX9/?@G2I"<4V[*=0^L@)X,A>R\",?*OM!Y<;BK$_39:9NELOOF&61XH;S%[
M1 X0/X(H0R5216WZR5 <OOGT-C3R5<DBBU-U5..#T'YK[S869G,YMI2(QL($
M[D,+ :)Q*4.1$PE3TPQ+18',XT2AS!24' FNR>"\3H ("BC!8[CO4L29>,/@
M00[?_+,9;:Y[PE78C(!02-'8OJNTJETP4TC=40+,$$IH*P56"1(0?D4'.=YO
M8#T1\$P+PZ],:I;%U!KT!AP)G).RB4R'\ #7B;D4@.KEP*-3&D_149'"EZD8
M:::S8 C," P[%K&& =#!#S V:-MC6XV+8X8&A%8<P!PTJ:!U!4P"+>(]#5J:
M@.MA=7,CF+7\CUU7Q28*@\])OX^C\22+NE7X#(\'$B>#B #FDG\EV6FX.3(-
MZZ2(]JY;D%2A@&XC_+79XUH@>$V"[T0+N,4,HKC=&Z_.HA3)3*H7)Y3/-4@R
M!50 N"P'^2QX.)*QU+ .>%P&LB/@W9#>,H?#+MJ#,:>1& 'R@?X&> )'C%^
M)K//F$H*#5,NWP>]R3@$Z8*Q*#'((E-@T6(70P'C,@3E2@![V*5IL%# Q$A%
M77*%"\SZ0*U$P1BHJR2+0C;D,'+.$'XIGTGB&7XUD]$D8LA6N<S!:LLD;+$/
M]H+F(V&Y$3JJ8%M 6-"8,9(:E(;L@\K!EJQZA#LON8SH=AD3)7&N#3892F!8
M,^R>*(8,;?:S%$3(#;+%SL<BH':C:.H- I1&@\0ER5+HQY,9<%-@GK P=I#
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M%=J R= #$7 H!IYBAL JT9B=[>?3==/'T82BA]*B,YI^D&A,31IY0B8#WLQ
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MDZ@G\F]>J1+%Y,\!($>HQFQ\G8_'0"J2!G=>2.F8$-)NP@"A,%/Y< LA(M_
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M>PK6)?1=2PK\ GN97^U&AY5CE.6]O^#HUR_?+MBGD[-3_/?]Z?'1Q_4I6?R
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MD!/S?;=;H)'RQ('CX53+0,)<#& @ 07."H8QLKMT];X"LZ0QY>\P)R%L) '
M"?@-F!Q0P/L72<BA76%#!R49M\F<", ];A/-8@F.%$,^[B>13%#@9R7;9@J'
M@D?I,*#TK5$P;I<;L2ON E*79%Q <JA:FL*LH#LN920&5D0GJ'Y&+O\S!-J
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M*4FQT4O"*?P9IJ/HW?\"4$L#!!0    ( #*#,EF9@Y#>FQ8  $%G   8
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M!2#:W3:92VEQ)%*5>CG"M2(,R.BX?)"'FKQ51F,=)X'$8L3ZZ45_ WJ\-TC
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M%T%88Y(QV10R6[&6%;G%D=W=MQ,UB5W7BN5RMR,8C0UBTK.2@'*Y:BW=>*,
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M/S;SXO\!4$L! A0#%     @ ,H,R61X(MZJ4 P  XPP  !$
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M2P$"% ,4    "  R@S)9V_^+Q'<K   ++0  %P              @ $G,
M;6US:2TR,#(T,#DQ.'@X:S P,2YJ<&=02P$"% ,4    "  R@S)9EF^^TXTK
M  ".=0$ &               @ '36P  ;6US:2TR,#(T,#DQ.'AE>#DY9#$N
M:'1M4$L! A0#%     @ ,H,R69F#D-Z;%@  06<  !@              ( !
MEH<  &UM<VDM,C R-# Y,3AX97@Y.60R+FAT;5!+!08     !P ' -@!  !G
%G@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>mmsi-20240918x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mmsi-20240918.xsd" xlink:type="simple"/>
    <context id="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000856982</identifier>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_87wxZxlS3k-thngWsKY_jg_2_1">0000856982</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_A3ydQl1A1UCW6xod3abACg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_4Iq6rLd72UKJYJMAOFBDWg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_NmcFN7QL8kGJ8YHc1sV_oA">2024-09-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_cDbhrTtptE-NW38RgEifug">Merit Medical Systems,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_zkdtkvHeTEmek2wnEWOAaQ_1_0">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_0HGl6QAlj0uvsfDvDepnnQ_1_2">0-18592</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_YJ-sTADoHkS472B9kDdh6A_1_4">87-0447695</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_jZ0DgiLzaEiQxHeBliG3cQ_1_0">1600 West Merit Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr__mXkUExE90ywR761_t2qug">South Jordan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_FGbqA6Mk2Ey641J8piek7A">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_NnwW4VXm1ECn1dYH2m8zvA_2_2">84095</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_e4PKTj8oWEmz5z0Hb47dMA">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_QHP38LXNVkC5WZP7CqOMwg">253-1600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_2P5xcf4T7EqFbzpmZvDnNg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_lqMM1pAYSEiFY3Ok-1zrZQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_7g5WBL9TeUCSw8humoZAIw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_gtKTWWl5TECZ2eN6hEe1qg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_ydXO0Gl2AECAO6VJJwUYvg_2_0">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Tc_HWh8ooKUAk6MXDUmtlW9Eg_2_2">MMSI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_nSyZqrO4FUKGhfslEP8LFw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_9_17_2024_To_9_17_2024_vzqWOqKyCkOkiHtKZfWLdw"
      id="Narr_80zT4SGSnU-R39Xwgo-FUg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
